Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02756546

Enrollment

100

Registered

2016-04-29

Start date

2014-09-30

Completion date

2015-12-31

Last updated

2016-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosis

Brief summary

This study aims to identify the expression signature of miR-181a, miR-196a and miR-21 in plasma of SLE patients and difference in their expression among groups with different systemic lupus erythematosis disease activity index (SLEDAI) scores.

Interventions

DRUGCyclophosphamide

DRUGHydroxychloroquine

DRUGHydrocortisone

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Adult systemic lupus erythematosis patients

Exclusion criteria

* Patients younger than 18 years, patients with other autoimmune diseases or malignancy.

Design outcomes

Primary

Measure	Time frame
MicroRNAs expression level	3 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026